Naoki Terada

Naoki Terada

Auto-generated profile, based on publicly available information

Naoki Terada

Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Urology
Verified
Journal Article
Closed access
NTNaoki Terada
Naoki Terada
YAYoichi Arai
Yoichi Arai
NKNaoko Kinukawa
Naoko Kinukawa
ATAkito Terai
Akito Terai

1 January 2002
Verified
Journal Article
Closed access
NTNaoki Terada
Naoki Terada
KIKentaro Ichioka
Kentaro Ichioka
YMYosuke Matsuta
Yosuke Matsuta
KOKazutoshi Okubo
Kazutoshi Okubo
KYKoji Yoshimura
Koji Yoshimura
YAYoichi Arai
Yoichi Arai

1 September 2007 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
TAKAHIRO INOUETAKAHIRO INOUE
TAKAHIRO INOUE
TKTakashi Kobayashi
Takashi Kobayashi
NTNaoki Terada
Naoki Terada
YSYosuke Shimizu
Yosuke Shimizu
TKToshiyuki Kamoto
Toshiyuki Kamoto
ENEijiro Nakamura
Eijiro Nakamura
Prostate cancer is one of the most frequently diagnosed cancers in the western world and this malignant neoplasm is the second-leading cause of cancer death among men in the USA. In the early 1940s, Huggins and Hodges demonstrated that growth and survival of prostate cancer depends on androgens. The mainstay of treatment for advanced prostate cancer is currently androgen ablation. Over the past few decades, several compounds, such as luteinizing hormone-releasing hormone analogues and anti-androgens, were developed and widely used in clinics. Then, the new treatment strategy, maximum androgen blockade (MAB) was introduced. In fact, MAB improved the prognosis of patients with advanced prostate cancer to some extent; however, most of those patients finally relapse after a period of initial response to this therapy, developing androgen-independent prostate cancer (AIPC). Once patients develop AIPC, effective therapeutic modalities are extremely limited and, therefore, the prognosis of this disease is very poor. It is strongly desirable to explore novel therapeutic concepts for AIPC, based on detailed molecular mechanisms for progression to androgen independency. As for the molecular mechanisms involved in the emergence of AIPC, mutations in the androgen receptor have been examined most extensively. These days, evidence is accumulating that demonstrates activation of signal transduction pathways, such as Src, PI3K and mTOR/S6K, are involved in the acquisition of the androgen-independent cell proliferation of prostate cancer cells. In addition, animal models using transgenic and gene-knockout techniques have confirmed these results. The development of therapies targeting against the signal transduction pathways is critical for the improvement of the prognosis of patients with AIPC. In this article, we review recent understandings on molecular mechanisms of androgen-dependent proliferation of prostate cancer cells, whose aberrant activation is proposed as a critical event for progression to AIPC.

1 May 2002
Verified
Journal Article
Closed access
KOKazutoshi Okubo
Kazutoshi Okubo
KOKeiji Ogura
Keiji Ogura
KIKentaro Ichioka
Kentaro Ichioka
NTNaoki Terada
Naoki Terada
YMYosuke Matsuta
Yosuke Matsuta
YUYou Umaoka
You Umaoka

12 October 2004 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
ATAkito Terai
Akito Terai
YMYoshiyuki Matsui
Yoshiyuki Matsui
KIKentaro Ichioka
Kentaro Ichioka
HOHiroki Ohara
Hiroki Ohara
NTNaoki Terada
Naoki Terada
KYKoji Yoshimura
Koji Yoshimura
Background: Prostate‐specific antigen doubling time (PSA‐DT) has been studied as a parameter reflecting the biological doubling rate of clinically localized prostate cancer treated expectantly. With the use of PSA‐DT, we studied the natural history of PSA changes among Japanese men in a health screening program. Methods: Between July 1994 and December 2002, a cohort of 1995 men aged 40–79 years underwent a total of 5700 PSA measurements in an annual multiphasic health screening program. Prostate‐specific antigen doubling time was calculated using a log‐linear regression model for 994 (49.8%) men who had three or more serial PSA measurements with a mean follow‐up of 46.2 months. Results: Of the 994 men, 192 (19.3%) had a PSA‐DT of less than 10 years and 12 (1.2%) had a PSA‐DT of less than 2 years. Median PSA‐DT in 14 men with a subsequent diagnosis of prostate cancer was 41.6 months (range, 12.2 to stable). A log‐linear model statistically fitted 65 of 180 non‐cancer patients with a PSA‐DT of less than 10 years. The percentages of statistically fit cases increased with higher baseline PSA (5.3%, 7.7% and 8.7% among men with <1.0, 1.0–1.99 and 2.0–3.99 ng/mL, respectively) and older baseline age (3.7%, 8.5% and 6.9% among ages 40–49, 50–59 and 60 or older, respectively). Conclusion: In a small but significant portion of men, PSA increases exponentially when it is still less than 4.0 ng/mL, with a PSA‐DT of less than 10 years. The clinical significance of this finding should be evaluated by a prospective screening including biopsy.

1 April 2003
Verified
Journal Article
Closed access
YMYosuke Matsuta
Yosuke Matsuta
KIKentaro Ichioka
Kentaro Ichioka
NTNaoki Terada
Naoki Terada
SMShinya Maekawa
Shinya Maekawa
KOKazutoshi Okubo
Kazutoshi Okubo
YAYoichi Arai
Yoichi Arai